Shah PK, N. Sirisha, Jayaraj S, and Sowdhamini R, “Structural Similarities in Protein Structures: Fold Prediction and Homology-Derived Modeling” Symposium on Bioinformatics at Avinashilingam University 1999.
Drug Discovery & Development
Mrowiec et al., “Digital pathology to evaluate PD-L1 IHC scoring as a predictor of outcome with second-line avelumab treatment in patients with non-small cell lung cancer”. ASCO 2020
Wolfe CM et al., “Enabling digital image analysis-based translational research with clinical legacy tissue scans” Submitted to ESDP 2020
Alimzhanov M et al., “Induction of immunogenic cell death and interferon signaling by Carboplatin and the ATR inhibitor M6620 may contribute to anti-tumor activity of M6620-Carboplatin-Avelumb triplet combination in MC38 tumor model” AACR 2020
Shah PK* et al, Development and validation of baseline predictive biomarkers for response to avelumab in second-line (2L) non-small cell lung cancer (NSCLC) Journal of ImmunoTherapy of Cancer SITC 2019
Shah PK* et al, Development and validation of baseline predictive biomarkers for response to immuno-checkpoint treatments in the context of multi-line and multi-therapy Journal of ImmunoTherapy of Cancer SITC 2019
Georges S, Shah PK et al., “Integrative molecular analysis of metastatic merkel cell carcinoma to identify predictive biomarkers of response to avelumab” ASCO 2019
Shah PK* et al., “Understanding contribution and independence of multiple biomarkers for predicting response to atezolizumab” ASCO 2019
Vangamudi et al., “The SMARCA2/4 catalytic activity, but not the bromodomain, is a drug target in SWI/SNF mutant cancers” AACR 2015.
Andersen JN, Shah PK et al., “Applying TCGA data for breast cancer diagnostics and pathway analysis” AACR 2014.
Multiple Myeloma
Song W et al., “Bone marrow microenvironment affects the pathogenesis of multiple myeloma through down-regulation of alternative splicing factor FOX2 in myeloma cells” BLOOD 2013 122(21): 3085.
Fulciniti M et al., “Functional and molecular impact of DP1-dependent alternate splicing in Multiple Myeloma” BLOOD 2013 122(21): 1845.
Song W et al, “Alternate splicing factor FOX2 affects growth and survival of Multiple Myeloma Cells” BLOOD 2011 118(21): 790-790.
Shah PK et al., “Are gene expression signatures treatment specific?” BLOOD 2011 118(21): 367-367.
Munshi NC et al., “Whole genome sequencing defines the clonal architecture and genomic evolution in Myeloma: Tumor heterogeneity with continued acquisition of new mutational change” BLOOD 2011 118(21): 367-367.
Shah PK et al., “Studying evolution of Multiple Myeloma with canEvolve” BLOOD 2011 118(21) 138-139.
Amin SB et al., “Gene expression profile alone is inadequate in predicting complete response in Multiple Myeloma” BLOOD 2010 116(21): 139-139.
Amin SB et al., “An integrative analysis of network motifs and gene expression data to discover experimentally testable transcription factor-miRNA-gene regulatory loops in Multiple Myeloma” BLOOD 2010 116(21), 802-802.
Shah PK et al., “A combined survival model integrating gene expression and alternative splicing events provides higher prediction power for risk stratification” BLOOD 2010 116(21), 803-803.
Shammas et al., “Evolution of genomic changes and their significance in myeloma” BLOOD 2009 114 (22): 250-251.
Adamia S et al., “Biological and therapeutic potential of miR-155, 585 and Let-7f in multiple myeloma in-vitro and in-vivo” BLOOD 2009 114(22): 343-343.
